Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 539151, 5 pages
http://dx.doi.org/10.1155/2014/539151
Research Article

Comparison of Commercial Genetic-Testing Services in Korea with 23andMe Service

Department of Laboratory Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Joowha-ro 170, Ilsanseo-gu, Goyang, Gyeonggi 411-706, Republic of Korea

Received 28 February 2014; Accepted 4 June 2014; Published 25 June 2014

Academic Editor: Giulio Mengozzi

Copyright © 2014 Sollip Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Imai, L. J. Kricka, and P. Fortina, “Concordance study of 3 direct-to-consumer genetic-testing services,” Clinical Chemistry, vol. 57, no. 3, pp. 518–521, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. C. Ng, S. S. Murray, S. Levy, and J. C. Venter, “An agenda for personalized medicine,” Nature, vol. 461, no. 7265, pp. 724–726, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Borry, “Statement of the ESHG on direct-to-consumer genetic testing for health-related purposes,” European Journal of Human Genetics, vol. 18, no. 12, pp. 1271–1273, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. A. C. Sturm and K. Manickam, “Direct-to-consumer personal genomic testing: a case study and practical recommendations for ‘genomic counseling’,” Journal of Genetic Counseling, vol. 21, no. 3, pp. 402–412, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. C. C. Chung and S. J. Chanock, “Current status of genome-wide association studies in cancer,” Human Genetics, vol. 130, no. 1, pp. 59–78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Li, “Personalized medicine—the promised land: are we there yet?” Clinical Genetics, vol. 79, no. 5, pp. 403–412, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. D. J. Kaufman, J. M. Bollinger, R. L. Dvoskin, and J. A. Scott, “Risky business: risk perception and the use of medical services among customers of DTC personal genetic testing,” Journal of Genetic Counseling, vol. 21, no. 3, pp. 413–422, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. T. A. Pearson and T. A. Manolio, “How to interpret a genome-wide association study,” Journal of the American Medical Association, vol. 299, no. 11, pp. 1335–1344, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. B. F. Gage, C. Eby, J. A. Johnson et al., “Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin,” Clinical Pharmacology and Therapeutics, vol. 84, no. 3, pp. 326–331, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. T. E. Klein, R. B. Altman, N. Eriksson, B. F. Gage, S. E. Kimmel, M. T. Lee et al., “Estimation of the warfarin dose with clinical and pharmacogenetic data,” The New England Journal of Medicine, vol. 360, pp. 753–764, 2009. View at Publisher · View at Google Scholar
  11. M. R. McClain, G. E. Palomaki, M. Piper, and J. E. Haddow, “A Rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding,” Genetics in Medicine, vol. 10, no. 2, pp. 89–98, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Healy, “FDA wins high-profile support in consumer genetics kerfuffle,” Los Angeles Times, March 2014, http://www.latimes.com/science/sciencenow/la-sci-sn-fda-consumer-genetics-20140313,0,3621735.story.